|Support type:||Scholarships in Brazil - Scientific Initiation|
|Effective date (Start):||October 01, 2018|
|Effective date (End):||September 30, 2019|
|Field of knowledge:||Biological Sciences - Morphology - Anatomy|
|Principal Investigator:||Valéria Helena Alves Cagnon Quitete|
|Grantee:||Felipe Rabelo Santos|
|Home Institution:||Instituto de Biologia (IB). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil|
Prostate cancer (PCa) is the second cause of death among men. During PCa development and progression several processes are involved, highlighting the inflammation. Molecules that participate in the inflammatory process lead to the glandular microenvironment changes, favoring the PCa development and progression. Among these molecules, cyclooxygenase-2 (COX-2) and inducible nitric oxide synthetase (iNOS) can be highlighted, which potentiate the carcinogenic process. Another relevant fact related to PCa progression is the ingestion of hyperlipidic diet, which also leads to inflammation process increase and consequently the proliferative process in the prostate. Functional foods have been related to cellular proliferation reduction and/or oxidative effects in the body. So, Jaboticaba, a Brazilian fruit which presents anti-inflammatory and antioxidant properties, resulting in beneficial effects for the body has been studied. Thus, the objective of the study herein is characterize the Jaboticaba peel extract effects, associated to the hyperlipidic diet ingestion in the ventral lobe of the prostate in the transgenic adenocarcinoma mouse prostate (TRAMP). This will be evaluated by means of morphological, proliferative process and COX-2 and iNOS immunohistochemical evaluation. For this, TRAMP mice will be divided into 5 experimental groups: control (C8), control and normal lipid diet (C16), Jaboticaba and normal lipid diet (JC), control and hyperlipidic diet (CH) and Jaboticaba and hyperlipidic diet (JH), and after the end of the experimental period, the animals will be sacrificed and the ventral lobe of the prostate will be collected. The prostate will be evaluated to light microscopy, morphometry and COX-2 and iNOS immunohistochemistry.